StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 12.6 %

Brooklyn ImmunoTherapeutics stock opened at $1.07 on Friday. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.88. The firm has a market cap of $62.94 million, a P/E ratio of -0.47 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.